Aigen Investment Management’s TG Therapeutics TGTX Stock Holding History

Aigen Investment Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,522	Closed	-$375K	–	1066
2025 Q1	$375K	Buy	+9,522	New	+$320K	0.06%	423
2024 Q3	–	Sell	-18,464	Closed	-$328K	–	1010
2024 Q2	$328K	Buy	18,464 +2,292	+14%	+$36.6K	0.06%	447
2024 Q1	$246K	Buy	+16,172	New	+$258K	0.05%	492
2023 Q4	–	Sell	-94,748	Closed	-$792K	–	1081
2023 Q3	$792K	Buy	94,748 +83,783	+764%	+$1.17M	0.15%	219
2023 Q2	$272K	Sell	10,965 -4,772	-30%	-$123K	0.04%	522
2023 Q1	$237K	Buy	+15,737	New	+$239K	0.03%	488
2021 Q1	–	Sell	-16,246	Closed	-$845K	–	878
2020 Q4	$845K	Buy	+16,246	New	+$549K	0.11%	245

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aigen Investment Management's TGTX Position: Q2 2025 in Review

Aigen Investment Management sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 9,522 shares — an estimated $375K sold.

Aigen Investment Management first reported a position in TGTX in Q4 2020 and held it in 7 quarters. The position peaked at $845K in Q4 2020. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

Aigen Investment Management reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
Aigen Investment Management sold 9,522 TG Therapeutics shares in Q2 2025, an estimated $375K.
Aigen Investment Management first reported a position in TG Therapeutics in Q4 2020 and held it in 7 quarters.
Aigen Investment Management's TG Therapeutics position peaked at $845K in Q4 2020.
356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Aigen Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.